Ker, James A.2015-09-232015-09-232015Ker. JA 2015, 'Is there a difference between an angiotensin-converting enzyme inhibitor and an angiotensin-specific receptor blocker for the treatment of hypertension?', South African Family Practice, vol. 57, no. 3, pp. 52-53.2078-6190 (print)2078-6204 (online)http://hdl.handle.net/2263/50030The renin-angiotensin system (RAS) and angiotensin II, in particular, play a central role and have been implicated in the spectrum of cardiovascular disease (CVD), beginning with hypertension, diabetes mellitus, atherosclerosis, myocardial infarction (MI), strokes and heart failure.en© 2015 The Author(s). Open Access article distributed under the terms of the Creative Commons License [CC BY-NC-ND 4.0].Angiotensin-specific receptor blockerRenin-angiotensin system (RAS)Cardiovascular disease (CVD)Angiotensin IIHypertensionDiabetes mellitusHeart failureAherosclerosisMyocardial infarction (MI)StrokesAngiotensin-converting enzyme inhibitor (ACE)Angiotensin-specific receptor blocker (ARB)Article